Heron Therapeutics Reports $8.1 Million Net Loss in Q1 2026

Heron Therapeutics, Inc. reported a net loss of $8.1 million for the first quarter of 2026, a significant decline from the net income of $2.6 million recorded in the same period of 2025. This resulted in a loss per share of $0.04, compared to earnings per share of $0.02 in the prior year. The company's total revenue from product sales decreased to $34.7 million, down 10.4% from $38.9 million in the first quarter of 2025. The decline in revenue was primarily driven by a 26.3% drop in oncology product sales, which fell to $21.1 million, while acute care product sales increased by 32.3% to $13.6 million, attributed to higher market share and new customer acquisitions for ZYNRELEF and APONVIE.

Operating expenses for the quarter rose to $28.8 million, up from $27.3 million in the previous year, with notable increases in sales and marketing expenses, which grew by 16.2% to $14.3 million. This increase was largely due to higher personnel costs and marketing efforts related to ZYNRELEF. Research and development expenses also saw a slight increase of 4.7% to $2.4 million, reflecting higher contract service costs. The cost of product sales increased by 25.8%, leading to a gross profit margin of 69.4%, down from 78.3% in the prior year.

In terms of strategic developments, Heron Therapeutics has continued to expand its product offerings and market presence. The company’s acute care product ZYNRELEF, which is approved for postoperative pain management, has seen increased adoption following its inclusion in the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, which allows for separate Medicare reimbursement. Additionally, APONVIE, approved for the prevention of postoperative nausea and vomiting, is set to receive a new permanent Healthcare Common Procedure Coding System J-code effective April 1, 2026, which is expected to enhance its market accessibility.

As of March 31, 2026, Heron reported cash, cash equivalents, and short-term investments totaling $44.8 million. The company has indicated that this liquidity is expected to meet its operational needs for at least the next year. However, the accumulated deficit has reached approximately $1.9 billion, raising concerns about the sustainability of its financial position. Looking ahead, Heron plans to focus on enhancing its product commercialization strategies and managing operational costs to improve its financial performance. The company remains committed to advancing its pipeline and exploring potential collaborations to bolster its market presence.